Song Andrew B, Al-Samkari Hanny
Harvard Medical School, Boston, Massachusetts, USA.
Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Br J Haematol. 2025 Apr;206(4):1062-1066. doi: 10.1111/bjh.20037. Epub 2025 Mar 4.
Chemotherapy-induced thrombocytopenia (CIT) is a common clinical problem in patients with solid tumour malignancies. Unlike nadir CIT which often resolves by the start of the following chemotherapy cycle, persistent CIT results in unacceptably low platelet counts at the beginning of a cycle lasting throughout multiple chemotherapy cycles, resulting in bleeding as well as chemotherapy treatment delays, dose reductions and discontinuation. Persistent CIT can be managed with thrombopoietin receptor agonist support in the context of a clinical trial or off-label use of romiplostim if a trial is not available.
化疗引起的血小板减少症（CIT）是实体瘤恶性肿瘤患者中常见的临床问题。与最低点CIT不同，后者通常在下一个化疗周期开始时缓解，持续性CIT会导致在整个多个化疗周期的一个周期开始时血小板计数低至不可接受的程度，从而导致出血以及化疗治疗延迟、剂量减少和停药。在临床试验的背景下，持续性CIT可以通过血小板生成素受体激动剂支持来管理，如果没有试验，也可以在标签外使用罗米司亭。
